Cited by 227Neuroscience and Neuropharmacology ResearchNicotinic Acetylcholine Receptors StudyNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index; none of the 222 sources its claims cite is checked for support yet.

An Emerging Circuit Pharmacology of GABAA Receptors

Open access
Engin, Elif, Benham, Rebecca S., Rudolph, Uwe·2018·Trends in Pharmacological Sciences

Abstract

In the last 20 years, we have learned a great deal about GABAA receptor (GABAAR) subtypes, and which behaviors are regulated or which drug effects are mediated by each subtype. However, the question of where in the brain the GABAARs involved in specific drug effects or behaviors are remains largely unanswered. Here we review recent studies taking a circuit pharmacology approach to investigate the functions of GABAAR subtypes in specific brain circuits controlling fear, anxiety, learning, memory, reward, addiction and stress related behaviors. The findings of the studies highlight the complexity of brain inhibitory systems and the importance of taking a subtype-, circuit-and neuronal population-specific approach to develop future therapeutic strategies using cell type-specific drug delivery.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This review argues that GABA_A receptor subtypes regulate fear, anxiety, learning, memory, reward, addiction, and stress-related behaviors in a subtype-, circuit-, and neuronal-population-specific manner. It concludes that circuit pharmacology of GABA_A receptors is emerging but still fragmentary, with findings often limited by contradictory results and incomplete anatomical specificity.

Key findings

  • In anxiety and fear circuits, α2GABAARs in dentate gyrus or CA3 principal neurons are required for diazepam-induced anxiolysis, whereas α2GABAARs in CA1 mediate diazepam-induced fear reduction; deletion in CA1 did not affect anxiolysis, and CA3/DG deletion did not affect fear reduction.
  • In learning and memory, α5GABAAR knockdown in CA3 or DG improved contextual fear memory, while DG granule-cell α5GABAAR knockdown impaired high-interference tasks such as context discrimination, reversal learning in a Morris water maze, and extinction of conditioned fear.
  • In reward and addiction, α2GABAARs in the nucleus accumbens are necessary to maintain midazolam preference in a two-bottle choice test, and α4GABAAR knockdown in the nucleus accumbens shell abolished ethanol self-administration in rats.
  • In stress and depression, global γ2 or α2 knockdown leads to anxiety- and despair-like behavior, δ subunit decreases in postpartum mice increase anxious- and depressive-like behavior and maternal neglect, and both positive and negative allosteric modulation of α5GABAARs can produce rapid antidepressant-like effects in chronically stressed rodents.

Methods

  • Narrative review of recent studies using a circuit pharmacology approach to investigate GABAAR subtypes in brain circuits controlling fear, anxiety, learning, memory, reward, addiction, and stress-related behaviors.
  • Synthesizes findings from gene-targeted mice, conditional knockout/knockdown, pharmacological manipulations, microinfusion, electrophysiology, and behavioral tasks; no primary experimental data are reported.
  • Main analysis is qualitative, organized by behavioral domain and brain circuit, with emphasis on subtype-, circuit-, and neuronal-population-specific effects.

Limitations

  • The paper states that knowledge of GABAAR subtype function within any behaviorally relevant circuit is “very fragmentary” and that the number of studies investigating anxiety- and fear-related behaviors through GABAAR subtypes in specific circuits or cell populations is “rather limited.”
  • The paper notes contradictory findings, such as for α3GABAARs in anxiety and for α2 subunits at the axon initial segment, and states that some evidence is confounded by technical limitations including compound selectivity or insufficient knockdowns.
  • Evident from the text: this is not a systematic review or meta-analysis, and it does not describe a formal search strategy, inclusion criteria, or quantitative synthesis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.tips.2018.04.003

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 222 cited sources checked · 0 supported · 0 flagged

Show all 118 claims

  • Probably not a substantial claim. 8
  • It may state two separate claims as one. 47
53 of 53
  • The paper relies on this without support.

    All GABAAR subtypes except α6 are expressed in varying cell groups and subregions of the amygdala.

    “All GABAAR subtypes, with the exception of α6GABAARs, are expressed in varying cell groups and subregions of the amygdala.”
  • The paper relies on this without support.

    α3GABAARs on LA principal neurons are localized preferentially extrasynaptically and mediate tonic inhibition.

    “Despite this, the α3GABAARs on LA principal neurons are localized preferentially exrasynaptically, mediating tonic inhibition.”
  • The paper relies on this without support.

    There are no studies to date that investigate the role of specific GABAAR subtypes within the circuitry of the mPFC, septum, thalamus, hypothalamus, periaqueductal grey, raphe nuclei and locus coeruleus.

    “However, to our knowledge, there are no studies to date that investigate the role of specific GABAAR subtypes within the circuitry of these areas.”
  • The paper relies on this without support.

    α2GABAARs are expressed on dendrites, soma and axon initial segment of principal neurons in all three hippocampal subregions, receiving input from different subtypes of interneuron depending on subcellular location.

    “α2GABAARs, which have been consistently implicated in the control of fear and anxiety, are expressed on the dendrites, soma and axon initial segment of principal neurons in all three hippocampal subregions, receiving input from different subtypes of interneuron depending on subcellular location.”
  • The paper relies on this without support.

    Circuit pharmacology studies in rodents can identify GABAAR subtypes and circuits relevant to human anxiety, fear, learning, memory, reward, addiction, and stress-related behaviors.

    “The findings of the studies highlight the complexity of brain inhibitory systems and the importance of taking a subtype-, circuit-and neuronal population-specific approach to develop future therapeutic strategies using cell type-specific drug delivery.”
  • The paper relies on this without support.

    Tonic inhibition in the DG is mediated through both α5GABAARs and α4/δGABAARs.

    “Given that tonic inhibition in the DG is mediated through both α5GABAARs and α4/δGABAARs, a natural question that comes to mind is: would α4/SGABAARs of the DG also play a similar role in managing memory interference, or is the specific pharmacology and expression pattern of α5GABAARs required for this process?”
  • The paper relies on this without support.

    The γ2 subunit is found in 90% of GABAARs.

    “While these studies are much more targeted than the global gene deletion studies discussed earlier, the γ2 subunit is found in 90% of GABAARs.”
  • The paper relies on this without support.

    α subtype selective compounds lack some side effects associated with nonselective GABAergic compounds such as sedation and tolerance.

    “Additionally, pharmacological compounds with α subtype selectivity are a promising potential therapeutic tool as they lack some of the side effects associated with nonselective GABAergic compounds such as sedation and tolerance.”
  • The paper relies on this without support.

    Activation of D1+ MSNs leads to positive reinforcement and enhances the rewarding properties of addictive drugs.

    “It has been demonstrated that the activation of D1+ MSNs leads to positive reinforcement and enhances the rewarding properties of addictive drugs, while the activation of D2+ MSNs may have the opposite effect (see [108] for a contradictory viewpoint).”
  • The paper relies on this without support.

    Activation of D2+ MSNs may have the opposite effect to D1+ MSN activation.

    “It has been demonstrated that the activation of D1+ MSNs leads to positive reinforcement and enhances the rewarding properties of addictive drugs, while the activation of D2+ MSNs may have the opposite effect (see [108] for a contradictory viewpoint).”
  • The paper relies on this without support.

    α4GABAARs are expressed in both D1+ and D2+ neurons.

    “While α4GABAARs are expressed in both D1+ and D2+ neurons, and have been shown to play opposing roles in the reinforcing properties of other drugs of abuse [115], the relative abundance of the receptor in the two neuronal populations is not clear.”
  • The paper relies on this without support.

    Neurosteroids modulate the activity of GABAARs.

    “As noted earlier, neurosteroids modulate the activity of GABAARs, and thus, ethanol may induce changes in the activity of GABAARs via its effect on neurosteroids, in addition to directly binding to GABAARs.”
  • The paper relies on this without support.

    Drugs of abuse exert their addictive actions through increasing dopamine levels in target structures and inducing synaptic plasticity in the VTA.

    “Drugs of abuse exert their addictive actions through increasing dopamine levels in target structures and inducing synaptic plasticity in the VTA.”
13 of 13

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 157 references

1 of the 157 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Fan, 2013, GABAA receptor α2 but not α1 subunit knock down in dentate gyrus reduces inhibition activity and improves learning abilities of rats, J. Mol. Neurosci., 51, S36

Cited by

Sorted by citations

Items 201–227 of 227

Metadata

Authors
Engin, E., Benham, R. S., & Rudolph, U.
Affiliations
Harvard University (US)
Corresponding author
  • Engin, Elif
  • Rudolph, Uwe
Venue
Trends in Pharmacological Sciences
Publisher
Elsevier BV
Published
2018-08
Volume
39
Issue
8
Pages
710-732
ISSN
0165-6147 (ISSN-L)
OpenAlex
W2807958215
Cited by
225
References
157
Citations by year
2026: 21 · 2025: 21 · 2024: 32 · 2023: 25 · 2022: 26 · 2021: 46 · 2020: 22 · 2019: 25 · 2018: 6
FWCI
3.24
Type
journal article
Language
en
Open access
Locations
  • Trends in Pharmacological Sciences (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Whitehall Foundation
  • Harvard Brain Science Initiative Bipolar Disorder Seed Grant
  • Brain and Behavior Research Foundation (19266))
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
GABAA receptor, GABA receptor subtypes, brain circuits, fear, anxiety, learning and memory, reward, addiction, stress behavior, inhibitory systems, treatment options
MeSH terms
Animals, Benzodiazepines, Brain, gamma-Aminobutyric Acid, Humans, Neurons, Receptors, GABA-A, GABA-A Receptor Agonists, GABA-A Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review